Phathom Pharmaceuticals (PHAT) Free Cash Flow (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Free Cash Flow of -$15.6 million for Q1 2026, up 81.58% year-over-year from -$8.6 million in Q1 2025, and down 202.12% quarter-over-quarter from -$5.2 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Free Cash Flow (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Free Cash Flow data on file, last reported at -$15.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$15.6 million, up 81.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$97.7 million (up 65.45% YoY), and the FY2025 annual result was -$167.0 million, up 37.43% from the prior year.
- Free Cash Flow declined to -$15.6 million in Q1 2026 per PHAT's latest filing, from -$5.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$5.2 million in Q4 2025 and troughed at -$84.9 million in Q1 2025.
- A 5-year average of -$43.2 million and a median of -$40.6 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow sank 218.49% in 2024, then surged 91.84% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$40.6 million in 2022, then declined by 5.19% to -$42.7 million in 2023, then plunged by 48.77% to -$63.5 million in 2024, then surged by 91.84% to -$5.2 million in 2025, then plunged by 202.12% to -$15.6 million in 2026.
- Business Quant data shows PHAT's Free Cash Flow at -$15.6 million in Q1 2026, -$5.2 million in Q4 2025, and -$14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -15.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.65 Mn |
| Mar 31, 2026 | -15.65 Mn |
| Dec 31, 2025 | -5.18 Mn |
| Dec 31, 2025 | -5.18 Mn |
| Sep 30, 2025 | -14.05 Mn |
| Sep 30, 2025 | -14.05 Mn |
| Jun 30, 2025 | -62.83 Mn |
| Jun 30, 2025 | -62.83 Mn |
| Mar 31, 2025 | -84.95 Mn |
| Mar 31, 2025 | -84.95 Mn |
| Dec 31, 2024 | -63.46 Mn |
| Dec 31, 2024 | -63.46 Mn |
| Sep 30, 2024 | -63.69 Mn |
| Sep 30, 2024 | -63.69 Mn |
| Jun 30, 2024 | -70.72 Mn |
| Jun 30, 2024 | -70.72 Mn |
| Mar 31, 2024 | -69.03 Mn |
| Mar 31, 2024 | -69.03 Mn |
| Dec 31, 2023 | -42.66 Mn |
| Dec 31, 2023 | -42.66 Mn |